Clinical trials: Vaginal Candidiasis
Candidiasis, Vulvovaginal
Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis
The study is focused to prove that the efficacy and safety of Clotrimazole vaginal tablet vs Fluconazole for the treatment of severe vulvovaginal candidiasis
- Trial name
- NCT02180828
- Testing
- Clotrimazole vaginal tablet, Fluconazole
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Peking University Shenzhen Hospital
Invasive Candidiasis, Mucocutaneous Candidiasis
Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment
This is a multicenter, open label, non-comparator, single arm study to evaluate the efficacy and safety of ibrexafungerp (SCY-078) in patients ≥ 18 years of age with a documented fungal disease that has been intolerant or…
- Conditions
- Invasive Candidiasis, Mucocutaneous Candidiasis, Coccidioidomycosis, Histoplasmosis
- Trial name
- FURI (NCT03059992)
- Testing
- Ibrexafungerp
- Where
- 37 sites in United States, Austria and 6 more
- Volunteers
- 233 people
- Sponsor
- Scynexis, Inc.
Vaginitis, Bacterial Vaginosis
Point of Care Diagnosis of Vaginal Infections
Vaginal infections are a common gynecologic issue and may cause significant symptoms and discomfort for individuals. Point of care tests are used to diagnose infections in the office, with an advantage of quick diagnosis and…
- Conditions
- Vaginitis, Bacterial Vaginosis, Yeast Vaginitis, Trichomonas Vaginitis
- Trial name
- PAT (NCT06438575)
- Testing
- Xpert® Xpress MVP test, Usual Care
- Where
- United States
- Volunteers
- 351 people
- Sponsor
- Sharon L Hillier
Recurrent Vulvovaginal Candidiasis
Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)
This study is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of oral ibrexafungerp (formerly "SCY-078") compared to placebo in female subjects 12 years and older…
- Trial name
- CANDLE (NCT04029116)
- Testing
- Fluconazole Tablet, IBREXAFUNGERP
- Where
- 25 sites in United States
- Volunteers
- 440 people
- Sponsor
- Scynexis, Inc.
Vulvovaginal Candidiasis
Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Vulvovaginal Candidiasis
The objectives of this study were to demonstrate comparable safety and efficacy of Terconazole Vaginal Suppositories, 80 mg and fluconazole in the treatment of subjects with severe vulvovaginal candidiasis.
- Trial name
- NCT02180100
- Testing
- Terconazole Vaginal Suppository, Fluconazole
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Peking University Shenzhen Hospital
Vulvovaginal Candidiasis, Candida Infection
Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp
This is a pharmacokinetic evaluation of lactating women after receiving two doses of Ibrexafungerp. The study population included healthy lactating females who were at least 10 days postpartum with a fully established milk supply…
- Conditions
- Vulvovaginal Candidiasis, Candida Infection, Vaginal Candidiasis
- Trial name
- NCT06954493
- Testing
- Ibrexafungerp
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Scynexis, Inc.
Vulvovaginal Candidiasis
Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis
This study will treat subjects with complicated VVC who have failed prior fluconazole therapy with Ibrexafungerp for 1, 3 or 7 days of treatment.
- Trial name
- NCT05399641
- Testing
- Ibrexafungerp
- Where
- 25 sites in United States
- Volunteers
- 150 people
- Sponsor
- Scynexis, Inc.